September 21, 2021
Company Info
| Industry | Biotechnology |
|---|---|
| Sector | Health Technology |
| Employees | 773 |
| CEO | Dr. Michael M. Morrissey |
| Address | 1851 Harbor Bay , Alameda, CA 94502 |
|---|---|
| Phone | 1.650.837.7000 |
| Website | www.exelixis.com |
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of COMETRIQ, CABOMETYX, COTELLIC, and MINNEBRO. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA.
Competitors
| Company Name | 3 Month %Change |
1 Year %Change |
|---|---|---|
| Exelixis, Inc. | -11.56% | -26.04% |
| Hill-Rom Holdings, Inc. | 33.92% | 82.11% |
| Bausch Health Cos., Inc. | -10.92% | 51.89% |
| United Therapeutics Corp. | 11.22% | 87.82% |
| Neurocrine Biosciences, Inc. | -5.22% | -6.28% |
Statement Summary
as of 4:00 ET PM 09/17/2021| Total Assets (MRQ) | 2.4 B |
|---|---|
| Total Liabilities (MRQ) | 324.2 M |
| Shareholders’ Equity (MRQ) | 2.0 B |
| Total Revenue (Annual) | 385.2 M |
| Net Income (Annual) | 96.1 M |
Earnings And Estimates
as of 4:00 ET PM 09/17/2021
| Current Qtr EPS Estimate | 0.13 |
|---|---|
| Current FY EPS Estimate | 0.60 |
| Long Term EPS Growth Estimate | 44.19 |
| Next Expected Earnings Date | 11/4/2021 |
EXEL vs S&P 500
as of 09/17/2021| Relative To S&P 500 |
EXEL | |
|---|---|---|
| 4 Weeks | n/a | n/a |
| 12 Weeks | n/a | n/a |
| YTD | n/a | n/a |
Earnings Surprises
as of 4:00 ET PM 09/17/2021| Fiscal Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 06/2021 | 0.06 | 0.30 | +393.15% |
| 03/2021 | 0.03 | 0.00 | -100.00% |
| 12/2020 | 0.06 | 0.09 | +57.14% |
| 09/2020 | 0.01 | -0.10 | -1,100.00% |
| 06/2020 | 0.12 | 0.21 | +73.96% |
| 03/2020 | 0.13 | 0.15 | +15.38% |
| 12/2019 | 0.17 | 0.22 | +32.97% |
| 09/2019 | 0.19 | 0.31 | +63.16% |
Financial Strength
as of 4:00 ET PM 09/17/2021| Pre-Tax Margin | 32.42 |
|---|---|
| Net Margin | -3.12 |
| Operating Margin | 31.94 |
| Return On Equity | 4.85 |
| Return On Assets | 4.26 |
| Inventory Turnover (TTM) | 2.20 |
| Sales Growth (MRQ) | 92.80 |
Ratios
as of 4:00 PM ET 09/17/2021| Price/Earnings (TTM) | 72.02 |
|---|---|
| Price/Book (MRQ) | 3.05 |
| Price/Cash Flow (TTM) | 23.51 |
| Book Value (MRQ) | 6.49 |
| Quick Ratio (MRQ) | 6.14 |
| Current Ratio (MRQ) | 6.24 |
| Total Debt/Equity (MRQ) | 0.03 |
Short Interest
as of 4:00 PM ET 09/20/2021| % Short - 0.00% | |
| % Remaining Float - 100.00% |
| Current | Last Month | |
|---|---|---|
| Short Interest Date | n/a | n/a |
| Short Interest Shares | 0 | 0 |
| Short Interest Ratio | 0.0 | 0.0 |
M Y M Y
Total Assets 0,0.00 0,0.00
Total Liabilities 0,0.00 0,0.00
Total Equity 0,0.00 0,0.00
M Y M Y
Total Revenue 0,0.00 0,0.00
EBT Exc.
Unusual Items
0,0.00
0,0.00
Net Income 0,0.00 0,0.00
M Y M Y
Cash from
Operations
0,0.00
0,0.00
Cash from
Activities
0,0.00
0,0.00
Cash from
Fin. Activities
0,0.00
0,0.00
TOTAL ASSETS |
TOTAL LIABILITIES |
TOTAL EQUITY |
|---|---|---|
Balance Sheet
| M Y | ||||
|---|---|---|---|---|
| ASSETS | ||||
| Cash And Equivalents | 0,0.00 | |||
| Receivables | 0,0.00 | |||
| Inventories | 0,0.00 | |||
| Other Current Assets | 0,0.00 | |||
| Total Current Assets | 0,0.00 | |||
| Property, Plant & Equipment, Gross | 0,0.00 | |||
| Accumulated Depreciation & Depletion | 0,0.00 | |||
| Property, Plant & Equipment, Net | 0,0.00 | |||
| Intangibles | 0,0.00 | |||
| Other Non-Current Assets | 0,0.00 | |||
| Total Non-Current Assets | 0,0.00 | |||
| TOTAL ASSETS | 0,0.00 | |||
| Liabilities & Shareholder Equity | ||||
| Accounts Payable | 0,0.00 | |||
| Short Term Debt | 0,0.00 | |||
| Total Current Liabilities | 0,0.00 | |||
| Long Term Debt | 0,0.00 | |||
| Deferred Income Taxes | 0,0.00 | |||
| Other Non-Current Liabilities | 0,0.00 | |||
| Minority Interest | 0,0.00 | |||
| Total Non-Current Liabilities | 0,0.00 | |||
| Preferred Stock Equity | 0,0.00 | |||
| Common Stock Equity | 0,0.00 | |||
| Common Par | 0,0.00 | |||
| Additional Paid In Capital | 0,0.00 | |||
| Cumulative Translation Adjustment | 0,0.00 | |||
| Retained Earnings | 0,0.00 | |||
| Treasury Stock | 0,0.00 | |||
| Other Equity Adjustments | 0,0.00 | |||
| Total Capitalization | 0,0.00 | |||
| TOTAL EQUITY | 0,0.00 | |||
| TOTAL LIABILITIES & STOCK EQUITY | 0,0.00 | |||
| Total Common Shares Outstanding | 0,0.00 | |||
| Preferred Shares | 0,0.00 | |||
| Treasury Shares | 0,0.00 | |||
| Basic Weighted Shares Outstanding | 0,0.00 | |||
| Diluted Weighted Shares Outstanding | 0,0.00 | |||
| Number Of Employees | 0,0.00 | |||
| Number Of Part-Time Employees | 0,0.00 | |||
TOTAL REVENUES |
EBT Excluding Unusual Items |
NET INCOME |
|---|---|---|
Income Statement
| M Y | |
|---|---|
| Sales | 0,0.00 |
| Cost Of Sales | 0,0.00 |
| Gross Operating Profit | 0,0.00 |
| Selling, General, And Administrative Expenses | 0,0.00 |
| Research & Development | 0,0.00 |
| Operating Income Before D & A (EBITDA) | 0,0.00 |
| Depreciation & Amortization | 0,0.00 |
| Interest Income | 0,0.00 |
| Other Income - Net | 0,0.00 |
| Special Income / Charges | 0,0.00 |
| Total Income Before Interest Expenses (EBIT) | 0,0.00 |
| Interest Expense | 0,0.00 |
| Pre-Tax Income | 0,0.00 |
| Income Taxes | 0,0.00 |
| Minority Interest | 0,0.00 |
| Net Income From Continuing Operations | 0,0.00 |
| Net Income From Discontinued Operations | 0,0.00 |
| Net Income From Total Operations | 0,0.00 |
| Extraordinary Income/Losses | 0,0.00 |
| Income From Cum. Effect Of Acct. Change | 0,0.00 |
| Income From Tax Loss Carryforward | 0,0.00 |
| Other Gains / Losses | 0,0.00 |
| Total Net Income | 0,0.00 |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
0,0.00 |
| Preferred Dividends | 0,0.00 |
| Net Income Available To Common | 0,0.00 |
| Basic EPS From Continuing Ops. | 0,0.00 |
| Basic EPS From Discontinued Ops. | 0,0.00 |
| Basic EPS From Total Operations | 0,0.00 |
| Basic EPS From Extraordinary Inc. | 0,0.00 |
| Basic EPS From Cum Effect Of Accounting Change | 0,0.00 |
| Basic EPS From Tax Loss Carryf'd. | 0,0.00 |
| Basic EPS From Other Gains (Losses) | 0,0.00 |
| Basic EPS, Total | 0,0.00 |
| Basic Normalized Net Income/Share | 0,0.00 |
| EPS From Continuing Ops. | 0,0.00 |
| EPS From Discontinued Ops | 0,0.00 |
| EPS From Total Ops. | 0,0.00 |
| EPS From Extraord. Inc. | 0,0.00 |
| EPS From Cum Effect of Accounting Change | 0,0.00 |
| EPS From Tax Loss Carfd. | 0,0.00 |
| EPS From Other Gains (L) | 0,0.00 |
| EPS, Total | 0,0.00 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
0,0.00 |
| Dividends Paid Per Share | 0,0.00 |
CASH FROM OPERATIONS |
CASH FROM INVESTING ACTIVITIES |
CASH FROM FINANCING ACTIVITIES |
|---|---|---|
Cash Flow Statement
| M Y | ||||
|---|---|---|---|---|
| Cash Flow From Operating Activities | ||||
| Net Income (Loss) | 0,0.00 | |||
| Operating Gains/Losses | 0,0.00 | |||
| Gross Operating Profit | 0,0.00 | |||
| (Increase) Decrease In Receivables | 0,0.00 | |||
| (Increase) Decrease In Inventories | 0,0.00 | |||
| (Increase) Decrease In Other Current Assets | 0,0.00 | |||
| (Decrease) Increase In Other Current Liabilities | 0,0.00 | |||
| (Increase) Decrease In Other Working Capital | 0,0.00 | |||
| Other Non-Cash Items | 0,0.00 | |||
| Net Cash From Continuing Operations | 0,0.00 | |||
| Net Cash From Discontinued Operations | 0,0.00 | |||
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | 0,0.00 | |||
| Sale Of Property, Plant & Equipment | 0,0.00 | |||
| Cash Used For Investing Activities | ||||
| Sale Of Short-Term Investments | 0,0.00 | |||
| Purchases Of Property, Plant & Equipment | 0,0.00 | |||
| Acquisitions | 0,0.00 | |||
| Purchases Of Short-Term Investments | 0,0.00 | |||
| Other Cash From Investing Activities | 0,0.00 | |||
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 0,0.00 | |||
| Issuance Of Debt | 0,0.00 | |||
| Cash Used For Financing Activities | ||||
| Issuance Of Capital Stock | 0,0.00 | |||
| Repayment Of Long-Term Debt | 0,0.00 | |||
| Repurchase Of Capital Stock | 0,0.00 | |||
| Payment Of Cash Dividends | 0,0.00 | |||
| Other Financing Charges, Net | 0,0.00 | |||
| Net Cash From Financing Activities | 0,0.00 | |||
| Effect Of Exchange Rate Changes | 0,0.00 | |||
| Net Change In Cash & Cash Equivalents | 0,0.00 | |||
Earnings Estimates
as of 4:00 ET PM 09/17/2021| Current Qtr (09/2021) |
Next Qtr (12/2021) |
|
|---|---|---|
| Consensus Estimate | $0.13 | $0.17 |
| # of Estimates | 12 | 12 |
| High Estimate | $0.23 | $0.30 |
| Low Estimate | $-0.03 | $0.08 |
| Year Ago EPS | $-0.10 | $0.09 |
| Year Over Year Growth Estimate | -227.09% | 86.00% |
| Current Yr (12/2021) |
Next Yr (12/2022) |
|
|---|---|---|
| Consensus Estimate | $0.60 | $0.94 |
| # of Estimates | 13 | 13 |
| High Estimate | $0.97 | $1.43 |
| Low Estimate | $0.18 | $0.45 |
| Year Ago EPS | $0.35 | $0.60 |
| Year Over Year Growth Estimate | 72.31% | 56.63% |
| Current Qtr (09/2021) |
Next Qtr (12/2021) |
Current Year (12/2021) |
Next Year (12/2022) |
|
|---|---|---|---|---|
| Consensus Estimate | $0.13 | $0.17 | $0.60 | $0.94 |
| # of Estimates | 12 | 12 | 13 | 13 |
| High Estimate | $0.23 | $0.30 | $0.97 | $1.43 |
| Low Estimate | $-0.03 | $0.08 | $0.18 | $0.45 |
| Year Ago EPS | $-0.10 | $0.09 | $0.35 | $0.60 |
| Year Over Year Growth Estimate | -227.09% | 86.00% | 72.31% | 56.63% |
Insider Information Summary
as of 08/31/2021| % Insiders - 2.49% | |
| % Remaining Total Shares - 97.51% |
| Current | 1 Month | |
|---|---|---|
| Net Insider Transaction | 155.00 K | 240.81 K |
| Shares Bought | 330.00 K | 678.89 K |
| Shares Sold | 175.00 K | 438.08 K |
Insider Activity
| Transaction Date | Insider/Title | Transaction Type | Market Value | Shares | Average Price | Current Holdings | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Trade with Jim Cramer 14 Days Free
Join the Action Alerts PLUS Community today!
LATEST NEWS
Latest News
Exelixis Statement On The Passing Of Two Senior Executives
- Sep 6, 2021 1:00 PM EDT
Recent Articles from TheStreet
Cramer's Mad Money Recap: Evergrande, Debt, Delta
Jim Cramer says don't get sucked into buying the dips. He can't be bullish until everyone else turns bearish, and we're still a long way away from that.
JPMorgan Says Stock Decline Represents Buying Opportunity
'Our fundamental thesis remains unchanged, and we see the sell-off as an opportunity to buy the dip,' said JPMorgan strategist Kolanovic.
Shell to Sell Permian Assets to ConocoPhillips for $9.5 Billion
Shell has signed an agreement to sell its Permian basin assets to ConocoPhillips for $9.5 billion cash.
Genmab, Seagen, Lennar, SmileDirect See After-Hours Moves
Drug makers gain on accelerated FDA approval for a cervical cancer treatment.
Jim Chanos Takes Short Position in Wynn on Macao Turmoil
'For years we’ve said people are ignoring that the concessions expiring next year [in Macao for casinos such as Wynn] are at risk,' Chanos said.
SPACs Are Seeing More Volatility Tied to Gamma Squeezes
But ‘Rev Shark’ cautions against the very high risk in such plays
Cramer: Something Strange is Happening With Oil
U.S. companies are stepping back from playing the swing producer role when oil prices rise.
Stock Market Today With Jim Cramer: Prepare to Buy What's Working
Jim Cramer discusses China's property developer Evergrande and other catalysts to Monday's selloff.
Goldman Lists Taiwan Semi Among its Top Chinese Chip Picks
Goldman Sachs likes Taiwan Semi for its strength in the three-nanometer processor market. It also selects United Microelectronics and ACM Research.
Palantir Stock Falls. To Buy the Dip, Here's the Support Level to Watch
Palantir stock had a good run and now is getting whacked. Let's look at where bulls may consider buying the dip.
CLOSE
CLOSE
CLOSE
CLOSE